343.80
+3.35
+(0.98%)
At close: 3:29:53 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
7,727,698
7,696,562
6,797,546
7,130,224
4,876,987
Cost of Revenue
3,830,459
3,992,924
3,409,039
4,228,168
2,555,067
Gross Profit
3,897,239
3,703,638
3,388,507
2,902,056
2,321,920
Operating Expense
2,624,412
2,392,102
2,235,198
1,611,058
1,640,440
Operating Income
1,272,827
1,311,536
1,153,309
1,290,998
681,480
Net Non Operating Interest Income Expense
-169,471
-139,478
-68,113
-34,866
-121,828
Pretax Income
1,107,375
1,156,715
1,067,209
1,268,383
577,115
Tax Provision
287,623
295,359
270,161
309,982
134,799
Net Income Common Stockholders
819,760
861,356
797,048
958,401
442,316
Diluted NI Available to Com Stockholders
819,760
861,356
797,048
958,401
442,316
Basic EPS
8.17
8.74
8.22
9.89
4.56
Diluted EPS
8.17
8.74
8.22
9.89
4.56
Basic Average Shares
100,244.82
98,519.94
96,944.51
96,944.51
96,944.51
Diluted Average Shares
100,244.82
98,519.94
96,944.51
96,944.51
96,944.51
Rent Expense Supplemental
--
14,700
13,368
23,910
10,444
Total Expenses
6,454,871
6,385,026
5,644,237
5,839,226
4,195,507
Net Income from Continuing & Discontinued Operation
819,760
861,356
797,048
958,401
442,316
Normalized Income
836,782.42
878,480.38
796,822.45
957,884.16
442,029.36
Interest Income
--
14,121
14,120
18,792
14,505
Interest Expense
175,630
145,637
66,357
40,064
117,657
Net Interest Income
-169,471
-139,478
-68,113
-34,866
-121,828
EBIT
1,283,005
1,302,352
1,133,566
1,308,447
694,772
EBITDA
1,458,638
1,472,524
1,356,377
1,497,737
857,848
Reconciled Cost of Revenue
3,830,459
3,992,924
3,409,039
4,228,168
2,555,067
Reconciled Depreciation
175,633
170,172
222,811
189,290
163,076
Net Income from Continuing Operation Net Minority Interest
819,760
861,356
797,048
958,401
442,316
Total Unusual Items Excluding Goodwill
-22,995
-22,995
302
684
374
Total Unusual Items
-22,995
-22,995
302
684
374
Normalized EBITDA
1,481,633
1,495,519
1,356,075
1,497,053
857,474
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-5,972.58
-5,870.62
76.45
167.16
87.36
3/31/2021 - 10/19/2004
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
GUJTHEM.NS Gujarat Themis Biosyn Limited
290.15
+4.18%
INDOCO.NS Indoco Remedies Limited
239.78
+2.70%
WINDLAS.BO Windlas Biotech Limited
1,066.90
-0.34%
INNOVACAP.NS Innova Captab Limited
903.65
+0.68%
WINDLAS.NS Windlas Biotech Limited
1,067.50
-0.21%
AMRUTANJAN.NS Amrutanjan Health Care Limited
685.40
+2.37%
NEULANDLAB.NS Neuland Laboratories Limited
12,749.00
+0.70%
ABBOTINDIA.NS Abbott India Limited
30,710.00
-0.78%
GLENMARK.NS Glenmark Pharmaceuticals Limited
1,356.80
-1.46%
WOCKPHARMA.NS Wockhardt Limited
1,392.40
-0.71%